These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2295 related articles for article (PubMed ID: 28360349)

  • 41. Role of the Gut Microbiome in Diabetes and Cardiovascular Diseases Including Restoration and Targeting Approaches- A Review.
    Alka Ahuja ; Saraswathy Mp ; Nandakumar S ; Prakash F A; Kn G; Um D
    Drug Metab Bioanal Lett; 2022; 15(3):133-149. PubMed ID: 36508273
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Gut macrobiotic and its metabolic pathways modulate cardiovascular disease.
    Zhu J; Lyu J; Zhao R; Liu G; Wang S
    Front Microbiol; 2023; 14():1272479. PubMed ID: 37822750
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of the Gut Microbiome in the Development of Atherosclerotic Cardiovascular Disease.
    Al Samarraie A; Pichette M; Rousseau G
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982492
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Emerging Roles of Gut Microbial Modulation of Bile Acid Composition in the Etiology of Cardiovascular Diseases.
    Yntema T; Koonen DPY; Kuipers F
    Nutrients; 2023 Apr; 15(8):. PubMed ID: 37111068
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of gut microbiota in cardiovascular diseases.
    Novakovic M; Rout A; Kingsley T; Kirchoff R; Singh A; Verma V; Kant R; Chaudhary R
    World J Cardiol; 2020 Apr; 12(4):110-122. PubMed ID: 32431782
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Diagnostics and therapeutic implications of gut microbiota alterations in cardiometabolic diseases.
    Schiattarella GG; Sannino A; Esposito G; Perrino C
    Trends Cardiovasc Med; 2019 Apr; 29(3):141-147. PubMed ID: 30126689
    [TBL] [Abstract][Full Text] [Related]  

  • 47. TMAO: how gut microbiota contributes to heart failure.
    Zhang Y; Wang Y; Ke B; Du J
    Transl Res; 2021 Feb; 228():109-125. PubMed ID: 32841736
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gut-microbiota derived bioactive metabolites and their functions in host physiology.
    Debnath N; Kumar R; Kumar A; Mehta PK; Yadav AK
    Biotechnol Genet Eng Rev; 2021 Oct; 37(2):105-153. PubMed ID: 34678130
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Disruptions in gut microbial-host co-metabolism and the development of metabolic disorders.
    Rajani C; Jia W
    Clin Sci (Lond); 2018 Apr; 132(7):791-811. PubMed ID: 29661926
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Human Gut Microbiota in Cardiovascular Disease.
    Ronen D; Rokach Y; Abedat S; Qadan A; Daana S; Amir O; Asleh R
    Compr Physiol; 2024 Jun; 14(3):5449-5490. PubMed ID: 39109979
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Connecting the immune system, systemic chronic inflammation and the gut microbiome: The role of sex.
    Rizzetto L; Fava F; Tuohy KM; Selmi C
    J Autoimmun; 2018 Aug; 92():12-34. PubMed ID: 29861127
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Importance of gut microbiota metabolites in the development of cardiovascular diseases (CVD).
    Hemmati M; Kashanipoor S; Mazaheri P; Alibabaei F; Babaeizad A; Asli S; Mohammadi S; Gorgin AH; Ghods K; Yousefi B; Eslami M
    Life Sci; 2023 Sep; 329():121947. PubMed ID: 37463653
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gut microbiota: a promising target against cardiometabolic diseases.
    Warmbrunn MV; Herrema H; Aron-Wisnewsky J; Soeters MR; Van Raalte DH; Nieuwdorp M
    Expert Rev Endocrinol Metab; 2020 Jan; 15(1):13-27. PubMed ID: 32066294
    [No Abstract]   [Full Text] [Related]  

  • 54. Gut Microbiota in Hypertension and Atherosclerosis: A Review.
    Verhaar BJH; Prodan A; Nieuwdorp M; Muller M
    Nutrients; 2020 Sep; 12(10):. PubMed ID: 33003455
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Gut-heart axis : How gut bacteria influence cardiovascular diseases].
    Bartolomaeus H; McParland V; Wilck N
    Herz; 2020 Apr; 45(2):134-141. PubMed ID: 32077981
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Microbiome Medicine: Microbiota in Development and Management of Cardiovascular Diseases.
    Garg Y; Kanwar N; Chopra S; Tambuwala MM; Dodiya H; Bhatia A; Kanwal A
    Endocr Metab Immune Disord Drug Targets; 2022; 22(14):1344-1356. PubMed ID: 35761484
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dietary lipids, gut microbiota and lipid metabolism.
    Schoeler M; Caesar R
    Rev Endocr Metab Disord; 2019 Dec; 20(4):461-472. PubMed ID: 31707624
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Update on gut microbiota in cardiovascular diseases.
    Qian B; Zhang K; Li Y; Sun K
    Front Cell Infect Microbiol; 2022; 12():1059349. PubMed ID: 36439214
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intestinal dysbiosis activates renal renin-angiotensin system contributing to incipient diabetic nephropathy.
    Lu CC; Ma KL; Ruan XZ; Liu BC
    Int J Med Sci; 2018; 15(8):816-822. PubMed ID: 30008592
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Unraveling mechanistic insights into the role of microbiome in neurogenic hypertension: A comprehensive review.
    Dai Y; Shen Z; Khachatryan LG; Vadiyan DE; Karampoor S; Mirzaei R
    Pathol Res Pract; 2023 Sep; 249():154740. PubMed ID: 37567034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 115.